Trial Profile
A open-label, parallel-arm, single-centre, cohort study evaluated the efficacy and safety of ombitasvir/paritaprevir/ritonavir ± ribavirin in patients with genotype-4 hepatitis C virus infection in Qatar
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2017
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 13 May 2016 New trial record
- 17 Apr 2016 Interim analysis (n=34) presented at The International Liver Congress™ 2016.